"Revolution Medicines reported Phase 3 clinical trial results for daraxonrasib, a drug targeting the KRAS protein mutation. The drug nearly doubled overall survival rates from 6.7 months to 13.2 months in patients with metastatic pancreatic cancer. The company plans to seek regulatory approval from the FDA and other global bodies."